Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Amylyx Pharmaceuticals, Inc. (AMLX) had Return on Tangible Equity of -10.81% for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-33.00M |
|
-- |
|
-- |
|
$36.60M |
|
$-36.60M |
|
$3.65M |
|
$-32.95M |
|
$-32.95M |
|
$-33.00M |
|
$-33.00M |
|
$-33.00M |
|
$-33.00M |
|
$-36.60M |
|
$-37.55M |
|
94.57M |
|
94.57M |
|
$-0.28 |
|
$-0.28 |
|
| Balance Sheet Financials | |
$323.67M |
|
$0.31M |
|
$8.97M |
|
$332.64M |
|
$22.69M |
|
-- |
|
$4.70M |
|
$27.39M |
|
$305.26M |
|
$305.26M |
|
$305.26M |
|
109.89M |
|
| Cash Flow Statement Financials | |
$-123.34M |
|
$14.04M |
|
$257.03M |
|
$78.84M |
|
$227.64M |
|
$148.80M |
|
$27.64M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
14.27 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-123.48M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-10.81% |
|
|
Return on Tangible Equity |
-10.81% |
-9.92% |
|
-10.81% |
|
$2.78 |
|
$-1.31 |
|
$-1.30 |
|